knowledg
risk
factor
communityacquir
pneumonia
risk
wors
outcom
import
manag
diseas
mental
ill
use
benzodiazepin
angiotensin
convert
enzym
inhibitor
recent
highlight
possibl
causal
link
pneumonia
period
studi
communityacquir
pneumonia
microbi
aetiolog
vital
confirm
whether
causal
pathogen
frequenc
chang
guid
empir
antibiot
therapi
strategi
prospect
populationbas
studi
spain
inpati
outpati
found
streptococcu
pneumonia
common
agent
follow
coxiella
burnetii
mycoplasma
pneumonia
respiratori
virus
chlamydia
speci
legionella
pneumophila
microbiolog
communityacquir
pneumonia
appear
unchang
found
earlier
studi
high
preval
c
burnetii
report
previou
studi
spain
patient
infect
convent
bacteria
pneumonia
higher
hospit
rate
higher
diseas
sever
score
admiss
advers
clinic
outcom
sever
sepsi
septic
shock
icu
admiss
longer
length
stay
compar
atyp
viral
caus
pneumonia
limit
studi
includ
absenc
sputum
cultur
possibl
popul
bia
total
outpati
communityacquir
pneumonia
episod
barcelona
recent
studi
aetiolog
establish
third
case
pneumonia
common
proven
pathogen
follow
mycoplasma
legionella
recent
case
report
saudi
arabia
led
discoveri
sixth
new
coronaviru
patient
pneumonia
acut
respiratori
distress
syndrom
multiorgan
dysfunct
syndrom
die
day
admiss
also
recent
refer
middl
east
respiratori
syndrom
coronaviru
human
coronaviruserasmu
medic
center
hcovemc
first
human
corona
viru
lineag
c
betacoronaviru
genu
closest
rel
coronavirus
found
bat
addit
case
middl
east
rais
concern
potenti
widespread
dissemin
bacteri
coinfect
present
consecut
adult
patient
hospit
diagnosi
influenza
communityacquir
pneumonia
predictor
bacteri
coinfect
includ
underli
chronic
obstruct
pulmonari
diseas
copd
higher
platelet
count
admiss
bacteri
coinfect
relat
increas
mortal
continu
caus
sporad
human
infect
egypt
south
east
asia
alarm
recent
emerg
caus
human
ill
case
report
far
suggest
link
bird
sourc
littl
humantohuman
spread
sever
multiorgan
failur
mortal
one
third
report
recent
systemat
review
show
standard
score
method
pneumonia
sever
index
psi
show
moder
good
accuraci
predict
mortal
patient
risk
death
see
tabl
detail
psi
appear
signific
advantag
term
neg
likelihood
ratio
therefor
indic
superior
abil
identifi
low
risk
patient
higher
posit
predict
valu
psi
system
suggest
may
superior
identifi
highrisk
patient
term
mortal
decis
regard
admiss
highrisk
patient
see
tabl
detail
antibiot
therapi
associ
signific
decreas
broadspectrum
antibiot
use
intervent
safe
impact
mortal
treatment
failur
clinic
respons
recent
studi
score
investig
whether
use
patient
lower
respiratori
tract
infect
primari
care
set
show
littl
correl
sever
symptom
durat
hospitalis
studi
howev
respiratori
rate
blood
pressur
infrequ
measur
respect
suggest
clinic
practic
would
chang
score
use
routin
anoth
studi
score
investig
whether
cut
age
impact
term
sever
patient
present
pneumonia
studi
includ
nearli
patient
hospitalis
germani
age
result
reason
threshold
assess
risk
death
communityacquir
pneumonia
total
popul
although
age
group
highest
risk
death
patient
age
less
year
death
predict
best
age
excel
predict
lowrisk
patient
patient
age
nurs
homeacquir
pneumonia
optim
age
group
death
predict
continu
american
thorac
societyinfecti
diseas
societi
america
atsidsa
rule
consist
two
major
mechan
ventil
shock
nine
minor
criteria
rule
consid
posit
presenc
one
major
three
minor
criteria
metaanalysi
found
at
minor
criteria
scommunityacquir
pneumonia
score
smartcop
good
predict
characterist
icu
admiss
recent
predict
cohort
studi
found
increas
serum
glucos
level
admiss
hospit
preexist
diabet
predictor
death
day
patient
communityacquir
pneumonia
whether
add
use
score
system
whether
blood
glucos
manag
alter
outcom
communityacquir
pneumonia
known
although
psi
score
system
includ
serum
glucos
paper
investig
serum
glucos
independ
risk
factor
predict
death
patient
communityacquir
pneumonia
systemat
review
procalcitonin
prognost
marker
communityacquir
pneumonia
found
complic
admiss
sever
diseas
death
within
month
correl
high
level
procalcitonin
definit
cut
level
found
procalcitonin
cutoff
point
ngml
best
predictor
bacteri
aetiolog
select
patient
elig
outpati
care
anoth
studi
suggest
level
procalcitonin
c
reactiv
protein
posit
correl
increas
sever
communityacquir
pneumonia
may
role
diseas
predict
perhap
patient
low
score
limit
studi
includ
studi
heterogen
risk
public
bia
use
procalcitonin
algorithm
antibiot
guidanc
reduc
antibiot
use
without
increas
complic
good
complianc
procalcitonin
algorithm
possibl
reallif
condit
reinforc
measur
achiev
optim
benefit
limit
includ
observ
design
unclear
diagnost
criteria
anoth
recent
studi
show
increas
proadrenomedullin
proadm
level
close
correl
increas
sever
score
show
predict
power
long
short
term
complic
patient
communityacquir
pneumonia
especi
use
conjunct
psi
admiss
proadm
level
nmol
correl
fashion
patient
psi
class
would
correctli
classifi
singl
hospit
studi
serial
biomark
use
throughout
studi
anoth
studi
also
reflect
proadm
may
help
individu
risk
stratif
communityacquir
pneumonia
patient
high
psi
score
emerg
depart
allow
better
identif
patient
risk
death
highest
level
lipopolysaccharidebind
protein
lbp
correl
best
score
accuraci
greatli
enhanc
use
level
best
use
predictor
sever
communityacquir
pneumonia
rather
prognosi
serum
cortisol
level
predict
mortal
critic
diseas
independ
clinic
score
inflammatori
biomark
recent
studi
show
increas
serum
cortisol
level
associ
develop
critic
diseas
increas
hospitalis
communityacquir
pneumoniapati
serum
cortisol
level
improv
predict
power
score
show
independ
prognost
signific
main
limit
studi
control
time
point
blood
sampl
could
done
diurnal
concentr
chang
may
influenc
result
see
tabl
comparison
select
featur
nation
intern
communityacquir
pneumonia
guidelin
drawn
guidelin
make
quit
clear
sever
ill
score
psi
use
identifi
patient
outpati
manag
physician
advis
take
account
factor
avail
outpati
support
resourc
score
suggest
hospit
admiss
direct
admiss
icu
made
upon
factor
septic
shock
requir
vasopressor
support
respiratori
failur
requir
intub
ventil
british
thorac
societi
bt
guidelin
quit
clear
score
system
conjunct
clinic
assess
main
requir
decid
point
care
admiss
communityacquir
pneumonia
patient
score
manag
quit
safe
outpati
patient
score
consid
hospit
admiss
signific
increas
mortal
group
score
review
senior
clinician
patient
score
serious
consid
icu
admiss
persist
hypoxia
progress
hypercapnoea
shock
reduc
conscious
indic
transfer
critic
care
guidelin
make
clear
decis
hospitalis
communityacquir
pneumonia
patient
clinic
decis
crb
score
except
age
criterion
met
suggest
hospitalis
consid
factor
acut
respiratori
failur
septic
shock
decompens
comorbid
consid
earli
referr
intens
care
alway
debat
regard
valu
singl
blactam
macrolid
versu
dual
blactam
plu
macrolid
antibiot
therapi
question
never
address
goodqual
randomis
control
trial
although
differ
antibiot
recommend
firstlin
treatment
guidelin
tabl
consensu
patient
sever
communityacquir
pneumonia
given
dual
therapi
total
studi
approxim
patient
includ
recent
metaanalysi
efficaci
macrolid
patient
hospitalis
communityacquir
pneumonia
macrolidebas
regimen
associ
signific
reduct
mortal
compar
nonmacrolid
howev
benefit
extend
randomis
control
trial
patient
receiv
guidelineconcord
antibiot
also
found
studi
communityacquir
pneumonia
patient
sever
sepsi
guidelineconcord
may
import
choic
antibiot
treat
communityacquir
pneumonia
studi
point
toward
need
good
adher
hospit
prescrib
guidelin
care
studi
conduct
came
verdict
benefit
dual
therapi
versu
singl
therapi
reliabl
assess
observ
studi
sinc
propens
prescrib
regimen
differ
markedli
take
account
may
skew
result
previou
studi
compar
singl
dual
therapi
total
patient
includ
audit
adult
communityacquir
pneumonia
manag
uk
death
rate
high
patient
treat
dual
therapi
significantli
lower
death
rate
moder
highsever
group
compar
therapi
alon
studi
propens
prescrib
could
correct
concord
find
cohort
studi
may
suggest
real
result
random
control
trial
result
requir
confirm
often
intervent
last
resort
fail
patient
studi
mening
pneumocysti
pneumonia
support
role
infect
control
recent
studi
communityacquir
pneumonia
absent
conflict
result
studi
sepsi
confirm
need
communityacquir
pneumoniaspecif
studi
prefer
randomis
control
trial
recent
doubl
blind
placebocontrol
random
control
trial
use
mg
prednisolon
day
intervent
found
benefici
effect
adjunct
corticosteroid
patient
hospit
communityacquir
pneumonia
outcom
studi
show
clinic
cure
equal
group
day
similar
studi
use
dexamethason
day
find
reduc
hospit
stay
one
day
steroidtr
patient
larg
number
exclus
lack
control
factor
limit
length
stay
limit
use
studi
randomis
control
trial
evalu
patient
communityacquir
pneumonia
admit
icu
found
reduct
mortal
use
hydrocortison
small
patient
number
absenc
death
intervent
arm
mean
find
generalis
unless
reproduc
studi
role
steroid
patient
communityacquir
pneumonia
yet
prove
pay
perform
program
adopt
intern
tri
improv
patient
outcom
limit
evid
effect
one
reason
may
lack
robust
evid
support
qualiti
indic
use
convers
us
studi
patient
associ
either
individu
combin
qualiti
indic
complianc
mortal
studi
inpati
mortal
amongst
adult
admit
pneumonia
heart
failur
acut
myocardi
infarct
uk
hospit
cover
payforperform
program
associ
use
program
signific
mortal
reduct
found
compar
uk
hospit
use
payforperform
program
three
includ
condit
howev
pneumonia
found
associ
mortal
reduct
payforperform
group
qualiti
measur
controversi
method
implement
random
control
trial
investig
implement
threestep
strategi
earli
mobilis
object
criteria
switch
oral
therapi
decid
hospit
discharg
show
interest
result
use
threestep
critic
pathway
safe
effect
reduc
durat
intraven
antibiot
therapi
length
hospit
stay
communityacquir
pneumonia
patient
advers
affect
patient
outcom
juri
still
regard
performancerel
programm
need
develop
randomis
control
trial
last
year
seen
major
advanc
manag
communityacquir
pneumonia
risk
stratif
patient
recent
advanc
addit
sever
use
biomark
issu
singl
versu
dual
antibiot
treatment
remain
controversi
await
conclus
random
control
trial
howev
meantim
work
consensu
sever
patient
receiv
dual
therapi
